Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Mohamed, AA; Thomsen, A; Follo, M; Zamboglou, C; Bronsert, P; Mostafa, H; Amen, A; Mekawy, M; Grosu, AL; Brunner, TB.
FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Strahlenther Onkol. 2021; 197(1): 27-38. Doi: 10.1007/s00066-020-01666-0 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Leading authors Med Uni Graz
Brunner Thomas Baptist
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
INTRODUCTION: Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase protein frequently overexpressed in cancer and has been linked to an increase in the stem cell population of tumors, resistance to therapy, and metastatic spread. Pharmacological FAK inhibition in pancreatic cancer has received increased attention over the last few years, either alone or in combination with other therapeutics including chemotherapy and immunotherapy. However, its prognostic value and its role in radioresistance of pancreatic ducal adenocarcinoma (PDAC) is unknown. METHODS AND MATERIALS: Using the TCGA and GTEx databases, we investigated the genetic alterations and mRNA expression levels of PTK2 (the encoding-gene for FAK) in normal pancreatic tissue and pancreatic cancer and its impact on patient survival. Furthermore, we evaluated the expression of FAK and its tyrosine domain Ty-397 in three pancreatic cancer cell lines. We went further and evaluated the role of a commercial FAK tyrosine kinase inhibitor VS-4718 on the viability and radiosensitization of the pancreatic cell lines as well as its effect on the extracellular matrix (ECM) production from the pancreatic stellate cells. Furthermore, we tested the effect of combining radiation with VS-4718 in a three-dimensional (3D) multicellular pancreatic tumor spheroid model. RESULTS: A database analysis revealed a relevant increase in genetic alterations and mRNA expression of the PTK2 in PDAC, which were associated with lower progression-free survival. In vitro, there was only variation in the basal phosphorylation level of FAK in cell lines. VS-4718 radiosensitized pancreatic cell lines only in the presence of ECM-producing pancreatic stellate cells and markedly reduced the ECM production in the stromal cells. Finally, using a 3D multicellular tumor model, the combination of VS-4718 and radiotherapy significantly reduced the growth of tumor aggregates. CONCLUSION: Pharmacological inhibition of FAK in pancreatic cancer could be a novel therapeutic strategy as our results show a radiosensitization effect of VS-4718 in vitro in a multicellular 2D- and in a 3D-model of pancreatic cancer.
Find related publications in this database (using NLM MeSH Indexing)
Aminopyridines - pharmacology
Antineoplastic Agents - pharmacology
Carcinoma, Pancreatic Ductal - drug therapy, enzymology
Cell Cycle - drug effects
Cell Line, Tumor - administration & dosage
Coculture Techniques - administration & dosage
Collagen - metabolism
Extracellular Matrix Proteins - metabolism
Focal Adhesion Kinase 1 - antagonists & inhibitors
Histones - analysis
Humans - administration & dosage
Kaplan-Meier Estimate - administration & dosage
Neoplasm Proteins - antagonists & inhibitors
Pancreatic Neoplasms - drug therapy, enzymology
Pancreatic Stellate Cells - drug effects, metabolism
Progression-Free Survival - administration & dosage
Protein Kinase Inhibitors - pharmacology
RNA Interference - administration & dosage
RNA, Messenger - biosynthesis
RNA, Neoplasm - biosynthesis
RNA, Small Interfering - genetics, pharmacology
Radiation Tolerance - drug effects
Radiation-Sensitizing Agents - pharmacology
Spheroids, Cellular - drug effects, radiation effects
Stromal Cells - drug effects
Tumor Stem Cell Assay - administration & dosage

Find related publications in this database (Keywords)
Pancreatic ductal adenocarcinoma
Focal adhesion kinase
Radiosensitization
Pancreatic stellate cell
Microenvironment
Stroma
© Med Uni GrazImprint